SCHEMBL23218860

SCHEMBL23218860

CCOC(=O)Cc1ccc(OC)cc1OCc1c2cc(Br)ccc2nn1C(C)C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.38
PDGFRB P09619 2/20 0.38
JAK2 O60674 1/20 0.38
PAK4 O96013 1/20 0.38
NTRK1 P04629 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
RET P07949 1/20 0.38
MET P08581 1/20 0.38
PIM1 P11309 1/20 0.38
FGFR1 P11362 1/20 0.38
PRKACA P17612 1/20 0.38
GRK5 P34947 1/20 0.38
MAP2K2 P36507 1/20 0.38
FLT3 P36888 1/20 0.38
MAPK8 P45983 1/20 0.38
CDK8 P49336 1/20 0.38
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
CDK7 P50613 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29853020 1.00 CSF1R (0.38) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL23218489 0.90 JAK2 (0.39) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL29852827 0.90 JAK2 (0.39) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL29853154 0.89 ALDH1A1 (0.39) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL23218889 0.89 ALDH1A1 (0.39) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL23218845 0.88 TBXAS1 (0.42) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL29592572 0.88 TBXAS1 (0.42) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL23218866 0.84 ELANE (0.41) CSF1RPDGFRBJAK2PAK4NTRK1
SCHEMBL23218411 0.83 CFD (0.46) CLK4ALDH1A1HPGDGAAKDM4E
SCHEMBL29852920 0.83 CFD (0.46) CLK4ALDH1A1HPGDGAAKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 US disclosed
EP-4041238-A1 ORAL COMPLEMENT FACTOR D INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2022-08-17 EP disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB CSF1R 340/4885PDGFRB 194/4885JAK2 4305/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB CSF1R 345/4885PDGFRB 956/4885JAK2 4719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.